Inactive Instrument

Delcath Systems, Inc. Stock price Nasdaq

Equities

US24661P1049

Medical Equipment, Supplies & Distribution

End-of-day quote Nasdaq
- USD 0.00% Intraday chart for Delcath Systems, Inc.
Sales 2024 * 25.91M Sales 2025 * 70.22M Capitalization 117M
Net income 2024 * -36M Net income 2025 * -14M EV / Sales 2024 * 4.52 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.67 x
P/E ratio 2024 *
-3.61 x
P/E ratio 2025 *
477 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.76%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 60 20-09-30
Director of Finance/CFO - 23-06-06
Compliance Officer - 22-01-24
Members of the board TitleAgeSince
Director/Board Member 81 08-12-04
Chief Executive Officer 60 20-09-30
Director/Board Member 58 20-02-13
More insiders
Delcath Systems, Inc. is an interventional oncology company. The Company is focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATO Kit is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is sold under the trade name CHEMOSAT Hepatic Delivery System for Melphalan (CHEMOSAT), where it has been used in the conduct of percutaneous hepatic perfusion procedures at medical centers to treat a range of cancers of the liver.
More about the company
  1. Stock
  2. Equities
  3. Stock Delcath Systems, Inc.
  4. Stock Delcath Systems, Inc. - Nasdaq